192 related articles for article (PubMed ID: 12869032)
1. BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.
Schultz H; Schinke S; Weiss J; Cerundolo V; Gross WL; Gadola S
Clin Exp Immunol; 2003 Aug; 133(2):252-9. PubMed ID: 12869032
[TBL] [Abstract][Full Text] [Related]
2. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL
Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
[TBL] [Abstract][Full Text] [Related]
3. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI).
Schultz H
Autoimmun Rev; 2007 Mar; 6(4):223-7. PubMed ID: 17317612
[TBL] [Abstract][Full Text] [Related]
4. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
Schultz H; Csernok E; Schuster A; Schmitz TS; Ernst M; Gross WL
Pediatr Allergy Immunol; 2000 May; 11(2):64-70. PubMed ID: 10893006
[TBL] [Abstract][Full Text] [Related]
5. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies.
Schultz H; Weiss J; Carroll SF; Gross WL
J Leukoc Biol; 2001 Apr; 69(4):505-12. PubMed ID: 11310835
[TBL] [Abstract][Full Text] [Related]
6. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.
Mahadeva R; Dunn AC; Westerbeek RC; Sharples L; Whitehouse DB; Carroll NR; Ross-Russell RI; Webb AK; Bilton D; Lomas DA; Lockwood CM
Clin Exp Immunol; 1999 Sep; 117(3):561-7. PubMed ID: 10469063
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein.
Schinke S; Fellermann K; Herlyn K; Reichel PH; Fundke R; Stange EF; Gross WL; Schultz H
Inflamm Bowel Dis; 2004 Nov; 10(6):763-70. PubMed ID: 15626895
[TBL] [Abstract][Full Text] [Related]
8. ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient.
Schultz H; Heintz H; van Zandbergen G; Ullrich S; Reinhold-Keller E; Gross WL
Clin Exp Rheumatol; 2003; 21(6):763-6. PubMed ID: 14740457
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies.
Carlsson M; Eriksson L; Erwander I; Wieslander J; Segelmark M
Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S95-100. PubMed ID: 14740434
[TBL] [Abstract][Full Text] [Related]
10. Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA.
Schultz H; Csernok E; Johnston TW; Lockwood CM; Gross WL
J Immunol Methods; 1997 Jul; 205(2):127-33. PubMed ID: 9294593
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.
Zhao MH; Jones SJ; Lockwood CM
Clin Exp Immunol; 1995 Jan; 99(1):49-56. PubMed ID: 7813109
[TBL] [Abstract][Full Text] [Related]
12. Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease.
Yang JJ; Tuttle R; Falk RJ; Jennette JC
Clin Exp Immunol; 1996 Jul; 105(1):125-31. PubMed ID: 8697620
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.
Khanna D; Aggarwal A; Bhakuni DS; Dayal R; Misra R
J Rheumatol; 2003 Jun; 30(6):1248-52. PubMed ID: 12784398
[TBL] [Abstract][Full Text] [Related]
14. Anti-neutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in patients with rheumatoid arthritis and their correlation with bronchial involvement.
Wada Y; Kuroda T; Murasawa A; Nakano M; Narita I
Mod Rheumatol; 2010 Jun; 20(3):252-6. PubMed ID: 20107854
[TBL] [Abstract][Full Text] [Related]
15. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis.
Sedivá A; Bartůnková J; Kolárová I; Hrusák O; Vávrová V; Macek M; Lockwood CM; Dunn AC
J Autoimmun; 1998 Apr; 11(2):185-90. PubMed ID: 9650098
[TBL] [Abstract][Full Text] [Related]
16. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin.
Cooper T; Savige J; Nassis L; Paspaliaris B; Neeson P; Neil J; Knight KR; Daskalakis M; Doery JC
Rheumatol Int; 2000; 19(4):129-36. PubMed ID: 10836522
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.
Carlsson M; Eriksson L; Pressler T; Kornfält R; Mared L; Meyer P; Wiik A; Wieslander J; Segelmark M
J Cyst Fibros; 2007 May; 6(3):228-33. PubMed ID: 17166780
[TBL] [Abstract][Full Text] [Related]
18. Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance.
Vecchi M; Sinico A; Bianchi MB; Radice A; Gionchetti P; Campieri M; de Franchis R
Scand J Gastroenterol; 1998 Dec; 33(12):1284-8. PubMed ID: 9930392
[TBL] [Abstract][Full Text] [Related]
19. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.
Walmsley RS; Zhao MH; Hamilton MI; Brownlee A; Chapman P; Pounder RE; Wakefield AJ; Lockwood CM
Gut; 1997 Jan; 40(1):105-9. PubMed ID: 9155585
[TBL] [Abstract][Full Text] [Related]
20. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis.
Dorlöchter L; Carlsson M; Olafsdottir EJ; Røksund OD; Rosendahl K; Fluge G
J Cyst Fibros; 2004 Aug; 3(3):179-83. PubMed ID: 15463905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
